Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18673969 | 0.87 | HTT (0.32) | SMPD3AXL | |
| SCHEMBL22461532 | 0.84 | HTT (0.33) | ALDH1A1 | |
| SCHEMBL9924212 | 0.82 | SMPD3 (0.36) | SMPD3AXLALDH1A1LMNAHSD17B10 | |
| SCHEMBL22388550 | 0.79 | HTT (0.44) | ALDH1A1HPGD | |
| SCHEMBL19863991 | 0.79 | SMPD3 (0.49) | SMPD3AXLALDH1A1LMNAHPGD | |
| SCHEMBL1499197 | 0.75 | SMPD3 (0.35) | SMPD3AXLALDH1A1LMNAHSD17B10 | |
| SCHEMBL9911040 | 0.72 | KDM4E (0.41) | SMPD3AXLALDH1A1LMNAHPGD | |
| SCHEMBL24654957 | 0.71 | JAK2 (0.34) | — | |
| SCHEMBL19155876 | 0.71 | NPC1 (0.35) | SMPD3AXLALDH1A1 | |
| SCHEMBL9124027 | 0.69 | SMPD3 (0.39) | SMPD3AXLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| US-9714231-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | SMPD3 842/4885AXL 3914/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.